Indraprastha Medical Corporation posts Q1 FY25 PAT at Rs. 44.77 Cr

Indraprastha Medical Corporation has reported total income of Rs. 352.98 crores during the quarter ended June 30, 2024

Cupid post Q1 FY25 profit at Rs. 8.25 Cr

Cupid Ltd has reported total income of Rs. 44.02 crores during the quarter ended June 30, 2024

SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr

SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024

Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular study

Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy

Roche closes acquisition of LumiraDx’s Point of Care technology

The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances

Divis Laboratories reports Q1 FY25 consolidated PAT at Rs. 430 Cr

Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024

Concerted efforts of individual and institutions needed for organ donation and transplantation: MoS Health Anupriya Patel

Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs

European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion

Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept

HCG Manavata Cancer Centre completes world-first in robotic-assisted nipple sparing mastectomy

AbbVie completes acquisition of Cerevel Therapeutics

Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia